Trial Profile

A retrospective study of efficacy and safety of olaparib with concurrent temozolomide in recurrent gliomas

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 18 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olaparib (Primary) ; Temozolomide (Primary) ; Bevacizumab; Pembrolizumab
Indications Astrocytoma; Glioblastoma; Glioma; Oligodendroglioma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

10 Aug 2022 Results assessing tolerability and efficacy of olaparib with temozolomide (TMZ) for glioma published in the Neurology
03 Jun 2022 New trial record
26 Apr 2022 Results presented at the 74th Annual Meeting of the American Academy of Neurology 2022

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com